
10
63
65
Processor
59
57
43e
43d
43c
43b
43a
61
53
55
54
32
52
36e
36d
36c
36b
36a
46
50
48
58
30
34
80
26
24

FIG. 1A


10
36e
36d
36c
36b
36a
34
42e
42d
42c
42b
42a
58
61
50
46
48
80
26
24
65
63
Processor
59
57
53
55
61
52
30
32

FIG. 1B


11
60
33d
33e
33c
33b
33a
62
36e
36d
36c
36b
61
36a
32
52
46
50
58
30
34
48
20
26
24
65
63
Processor
59

FIG. 2



FIG. 3A



FIG. 3B



FIG. 3C



FIG. 3D


82a 82b 82c 82d 82e 82f
Ligand 1
Ligand 2
Ligand 3
Ligand 4
Ligand 5
Reference
80

FIG. 4A


82a 82b 82c 82d 82e 82f
Ligand 1
Ligand 2
Ligand 3
Ligand 4
Ligand 5
Reference

FIG. 4B

FIG. 5A



FIG. 5B



FIG. 5C



FIG. 5D

Ligand 4

ka =2.4 x 10^{6} 1/MS kd =2.68 x 10^{-4} 1/s Chi^{2}=11.8



FIG. 5E

Ligand 5

ka = 8.98 x 10^{5} 1/MS kd =2.5 x 10^{-4} 1/s Chi^{2}=14.6



FIG. 5F

Ligand 6

ka =1.46 x 10^{6} 1/MS kd =2.12 x 10^{-4} 1/s Chi^{2}=7.54



SUBSTITUTE SHEET (RULE 26)



FIG. 6A



FIG. 6B



FIG. 6C



FIG. 6D



FIG. 6E

1 - **IgG1(anti Il-2)**
2 - **IgG1(anti IL-4)**
3 - **IgG2a**
4 - **IgG2b**
5 - **IgG3**
6 - **IgG polyclonal**

BEST AVAILABLE COPY



FIG. 7A



FIG. 7B



FIG. 7C

BEST AVAILABLE COPY



FIG. 7D



FIG. 7E



FIG. 7F